Larvol Delta - Modulation-of-leukemia-inhibitory-factor-LIF-pathway-in-patients-treated-with-tildrakizumab-brodalumab-and-methotrexate-A-potential-marker-of-cardiovascular-inflammation-improvement-under-tildrakizumab-treatment

methotrexate - Generic mfg.

Ilumya (tildrakizumab-asmn) - Sun Pharma, Almirall

Siliq (brodalumab) - Bausch Health

https://pagv3.virtual-meeting.org/eadv/eadvcongress2026/en-GB/pag/presentation/63296

Manuel Sanchez-Diaz

Aug 6, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next